Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4

80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4

Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4

300 mg BID (twice daily) orally

Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.